Michael Daneshvar (@uromadmd) 's Twitter Profile
Michael Daneshvar

@uromadmd

@UCI_Urology Urologic Oncologist, @NCICCR_UroOnc SUO Fellow via @UrologyUpstate

ID: 1126351020362272768

calendar_today09-05-2019 04:59:44

285 Tweet

689 Followers

849 Following

Jaime Landman (@jaimelandmanuci) 's Twitter Profile Photo

URPS MASTERS Drs. Kobiashi, Ghoniem, Chang and Sadeghi with UCI Urology faculty. Thanks KK for being amazing VP! Welcome back home!

URPS MASTERS Drs. Kobiashi, Ghoniem, Chang and Sadeghi with UCI Urology faculty.  Thanks KK for being amazing VP!  Welcome back home!
Michael Daneshvar (@uromadmd) 's Twitter Profile Photo

Just returned from #KCRS24. What an excellent meeting. Translational research ✅ kidney cancer advocacy ✅ seeing friends and thought leaders ✅ can’t wait for #KCRS25! KidneyCAN Mehdi Mollapour PhD Rebecca Sager Bryan Lewis #GennadyBratslavsky

Just returned from #KCRS24. What an excellent meeting. Translational research ✅ kidney cancer advocacy ✅ seeing friends and thought leaders ✅ can’t wait for #KCRS25! <a href="/kidneycan/">KidneyCAN</a> <a href="/MedMol/">Mehdi Mollapour PhD</a> <a href="/BeckySagerMDPhD/">Rebecca Sager</a> <a href="/advocatekidneys/">Bryan Lewis</a> #GennadyBratslavsky
Hanan Goldberg (@goldberghanan) 's Twitter Profile Photo

Proud of our recent Nature Urology review with great input by brilliant Roger Li & Petros Grivas exploring a rare & important entity of metastatic NMIBC. More biomarker driven research will help diagnose these more appropriately.Upstate Cancer Center Upstate Medical University Upstate Research

Proud of our recent Nature Urology review with great input by  brilliant <a href="/UrogerliMD/">Roger Li</a> &amp; <a href="/PGrivasMDPhD/">Petros Grivas</a> exploring a rare &amp; important entity of metastatic NMIBC. More biomarker driven research will help diagnose these more appropriately.<a href="/UpstateCancer/">Upstate Cancer Center</a> <a href="/UpstateNews/">Upstate Medical University</a> <a href="/InnovateUpstate/">Upstate Research</a>
Roger Li (@urogerlimd) 's Twitter Profile Photo

Wonderful collaboration with Hanan Goldberg Petros Grivas on an important topic Devastating situation for patients to develop metastases while on surveillance for #NMIBC We need to understand this disease process to better monitor our patients. Biomarkers will be the 🔑

Zach Klaassen (@zklaassen_md) 's Twitter Profile Photo

En route to Philly for the Consens UroToday.com Prostate Cancer Foundation 2025 GU Oncology Early Career Thought Leaders Conference -- going to be a great 2 days! Incredible faculty, attendees, and industry partners making this event possible Andrea Apolo, M.D.

En route to Philly for the Consens <a href="/urotoday/">UroToday.com</a> <a href="/PCFnews/">Prostate Cancer Foundation</a>   2025 GU Oncology Early Career Thought Leaders Conference -- going to be a great 2 days!

Incredible faculty, attendees, and industry partners making this event possible 
<a href="/apolo_andrea/">Andrea Apolo, M.D.</a>
Michael Daneshvar (@uromadmd) 's Twitter Profile Photo

Thank you to both Andrea Apolo, M.D. & Zach Klaassen for a great meeting! GU Oncology Early Career Thought Leaders Conference was well worth it! Looking forward to the conference in 2026!

Thank you to both <a href="/apolo_andrea/">Andrea Apolo, M.D.</a> &amp; <a href="/zklaassen_md/">Zach Klaassen</a> for a great meeting! GU Oncology Early Career Thought Leaders Conference was well worth it! Looking forward to the conference in 2026!
Daniel E Spratt (@drspratticus) 's Twitter Profile Photo

X-torial: Cleaning up the misinformation about Joe Biden and #ProstateCancer that I am reading everywhere. The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA National Comprehensive Cancer Network (NCCN) PCa guidelines, hold leadership in NRG Oncology National Cancer Institute

Sandeep Gurram (@sandeepgurrammd) 's Twitter Profile Photo

Excited to share our work performed at National Cancer Institute addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! nejm.org/doi/full/10.10…

Excited to share our work performed at <a href="/theNCI/">National Cancer Institute</a> addressing needs of rare hereditary kidney cancer through bench to bedside work

Bevacizumab + erlotinib for #HLRCC assoc RCC
📍Response rate 72%
📍mPFS 21.1 mo

Thanks to the patients who supported the study!
nejm.org/doi/full/10.10…